Statement of Comprehensive Income

Comprehensive income is the change in equity (net assets) of a business enterprise during a period from transactions and other events and circumstances from non-owners sources. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners.

Regeneron Pharmaceuticals Inc., consolidated statement of comprehensive income

US$ in thousands

12 months ended:	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net income	4,412,600)	3,953,600)	4,338,400)	8,075,300)	3,513,200)
Unrealized gain (loss) on debt securities	73,600)	158,200)	(213,600)	(56,400)	9,100)
Gain (loss) on foreign currency translation	(600)	(300)	—)	—)	—)
Unrealized gain (loss) on cash flow hedges	—)	—)	1,000)	900)	(900)
Other comprehensive income (loss), net of tax	73,000)	157,900)	(212,600)	(55,500)	8,200)
Comprehensive income	4,485,600)	4,111,500)	4,125,800)	8,019,800)	3,521,400)

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Download chart

Comprehensive income item	Description	The company
Net income	The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.	Regeneron Pharmaceuticals Inc. net income decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.
Comprehensive income	Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Exclude changes in equity resulting from investments by owners and distributions to owners.	Regeneron Pharmaceuticals Inc. comprehensive income decreased from 2022 to 2023 but then increased from 2023 to 2024 exceeding 2022 level.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)

Statement of Comprehensive Income